Marinomed Biotech

Valuation Analysis

About the Company

Marinomed Biotech en bref

Marinomed Biotech (MARI.VI) is currently trading at 9,35 € with a market capitalization of 16 M €. The trailing P/E ratio stands at 1.72x, with a forward P/E of 4.08x. The 52-week range spans from 8,60 € to 21,00 €; the current price is 55.5% below the yearly high. Year-over-year revenue growth stands at -76.9%. The net profit margin stands at 226.36%.

💰 Dividende

Marinomed Biotech currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

1 analystes évaluent Marinomed Biotech (MARI.VI) au consensus : None. L'objectif de cours moyen est de 50,00 €, soit un potentiel de +434.76% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 50,00 € à 50,00 €.

Marinomed Biotech : la thèse d'investissement en détail

Marinomed Biotech (MARI.VI) operates in the Healthcare — specifically Biotechnology — and is headquartered in Austria. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 82.15%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

Le scénario baissier

Revenue is contracting at -76.9% year-over-year — until that trend reverses, valuation is exposed to further downgrades.

Valorisation en contexte

The EV/EBITDA multiple of 586.86x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 434.76% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Trading Data

Related Stocks in the Same Sector

Where can I buy Marinomed Biotech?

Compare top-rated brokers — low fees, trusted providers, fully regulated.